Affiliations 

  • 1 Department of Pharmaceutical Life Sciences, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, 50603, Malaysia
  • 2 Sunway Microbiome Centre, School of Medical and Life Sciences, Sunway University, Subang Jaya, 47500, Selangor, Malaysia
  • 3 Pre-University Programmes, Sunway College Johor Bahru, Jalan Austin Heights Utama, Taman Mount Austin, 81100, JohorBahru, Johor, Malaysia
  • 4 School of Pharmacy, Monash University Malaysia, Bandar Sunway, Subang Jaya, 47500, Malaysia
  • 5 Department of Pharmacy, State University of Bangladesh, 77, Satmasjid Road, Dhanmondi, Dhaka1205, Bangladesh
  • 6 Pharmacology Unit, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, 47500, Subang Jaya, Selangor, Malaysia
  • 7 Centre of Excellence for Biomaterials Engineering, Faculty of Pharmacy, AIMST University, Bedong, 08100, Kedah, Malaysia
  • 8 Faculty of Pharmacy, AIMST University, Semeling, Bedong, Kedah, 08100, Malaysia
  • 9 Faculty of Chemical Engineering Technology, Universiti Malaysia Perlis, Arau, 02600, Perlis, Malaysia
PMID: 38494932 DOI: 10.2174/0115680096290673240223043650

Abstract

Despite decades of research and effort, treating cancer is still a challenging task. Current conventional treatments are still unsatisfactory to fully eliminate and prevent re-emergence or relapses, and targeted or personalised therapy, which are more effective in managing cancer, may be unattainable or inaccessible for some. In the past, research in natural products have yielded some of the most commonly used cancer treatment drugs known today. Hence it is possible more are awaiting to be discovered. Withanone, a common withanolide found in the Ayurvedic herb Withania somnifera, has been claimed to possess multiple benefits capable of treating cancer. This review focuses on the potential of withanone as a safe cancer treatment drug based on the pharmacokinetic profile and molecular mechanisms of actions of withanone. Through these in silico and in vitro studies discussed in this review, withanone showspotent anticancer activities and interactions with molecular targets involved in cancer progression. Furthermore, some evidences also show the selective killing property of withanone, which highlights the safety and specificity of withanone in targeting cancer cell. By compiling these evidences, this review hopes to spark interest for future research to be conducted in more extensive studies involving withanone to generate more data, especially involving in vivo experiments and toxicity evaluation of withanone.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.